Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
CL

AMEX · CLDI

Calidi Biotherapeutics, Inc.

Healthcare · Biotechnology

$0.73

Up+$0.00 (+0.13%)

Updated Nov 5, 2026, 8:18 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.39M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.10 – $1.93
Volume
43.56K
Avg. volume
161.89K

Price performance · CLDI

CLDI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

CLDI closed at $0.73 after 21 trading sessions, down 27.73% for the selected period.

Last close
$0.73
Period change
-27.73%
Period low
$0.64
Period high
$1.04
Daily close
View OHLC price history
CLDI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.76$0.792$0.6503$0.7343.56K
Nov 3, 2026$0.6298$0.7599$0.6298$0.74953.5K
Nov 2, 2026$0.6983$0.7097$0.6485$0.65833.05K
Oct 30, 2026$0.667$0.688$0.6446$0.68848.42K
Oct 29, 2026$0.65$0.7056$0.65$0.671720.94K
Oct 28, 2026$0.6996$0.7189$0.664$0.701827.59K
Oct 27, 2026$0.669$0.70$0.6225$0.6631.28K
Oct 26, 2026$0.65$0.65$0.63$0.6448.44K
Oct 23, 2026$0.65$0.66$0.6293$0.64543.8K
Oct 22, 2026$0.77$0.77$0.62$0.6499201.07K
Oct 21, 2026$0.759$0.7899$0.731$0.76863.66K
Oct 20, 2026$0.75$0.7793$0.75$0.7727.09K
Oct 19, 2026$0.801$0.8311$0.751$0.783454.81K
Oct 16, 2026$0.8897$0.8897$0.79$0.83735.2K
Oct 15, 2026$0.87$0.8899$0.8566$0.870123.95K
Oct 14, 2026$0.90$0.9199$0.82$0.87452.88K
Oct 13, 2026$0.9327$0.9327$0.87$0.899965.85K
Oct 12, 2026$0.998$0.998$0.9371$0.949953.58K
Oct 9, 2026$1.04$1.05$1.03$1.0318.07K
Oct 8, 2026$1.02$1.0414$1.00$1.0418.25K
Oct 7, 2026$1.02$1.03$0.986$1.0151.46K

Latest CLDI news

The latest Smart Investors Daily articles mentioning CLDI.

Stock researchCompany · Overview

CLDI research

Overview

Company profile and research snapshot.

Company profile

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
CLDI recent ratings
DateFirmRatingTarget
Jun 27, 2024Ladenburg ThalmannBuy—
May 15, 2024BairdOutperform—
Mar 21, 2024BairdOutperform—
Mar 21, 2024HC Wainwright & Co.Buy—
Nov 22, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform generated approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors following IV delivery, without systemic administration of the TCE protein itself, turning the tumor into a localized TCE biofactory SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, I

Yahoo · Oct 19, 2026

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. The presentations will showcase the Company’s RedTail platform, a systemically delivered virotherapy platform engineered t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By